Reshaping Resistance: How Autovaccine Therapy Alters the Course of Recurrent Multidrug-Resistant Urinary Tract...

Area of Science:

• Infectious Diseases
• Immunology
• Urology

Background:

• Multidrug-resistant (MDR) bacteria cause challenging urinary tract infections (UTIs) with high treatment failure and costs.
• Recurrent UTIs necessitate novel therapeutic strategies to mitigate antibiotic resistance and healthcare burdens.

Purpose of the Study:

• To evaluate the efficacy of personalized autovaccine therapy for recurrent UTIs in patients with MDR bacterial infections.
• To assess the impact of autovaccine therapy on infection recurrence, antibiotic consumption, and hospitalization rates.

Main Methods:

• A prospective, single-center study involving 40 patients with recurrent MDR UTIs.
• Administration of personalized sublingual autovaccines derived from patient-specific bacterial isolates.
• Assessment of UTI recurrence, antibiotic use, and hospitalization days over a 12-month period.

Main Results:

• Autovaccine therapy led to a significant reduction in UTI recurrence, observed in 67.5% of patients.
• A substantial decrease in antibiotic usage (74.4%) and annual hospitalization days (from 400 to 216) was recorded.
• A notable shift in bacterial profiles from MDR to multi-susceptible organisms was observed post-treatment.

Conclusions:

• Autovaccine therapy presents a safe and effective strategy for managing recurrent UTIs attributed to MDR bacteria.
• This approach significantly reduces infection frequency, antibiotic dependence, and hospital admissions.
• Findings support the integration of autovaccine therapy into standard UTI management to combat antibiotic resistance and alleviate healthcare system strain.